WEHI-345
WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation[1].
Product Specifications
CAS Number
[1354825-58-3]
UNSPSC
12352005
Target
RIP kinase
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/WEHI-345.html
Concentration
10mM
Purity
99.31
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=NC=C1)NCC(C)(N2N=C(C3=CC=C(C)C=C3)C4=C(N)N=CN=C42)C
Molecular Formula
C22H23N7O
Molecular Weight
401.46
References & Citations
[1]Nachbur U, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human anti-mitochondrial antibody M2 subtype (AMA-M2) ELISA Kit
Human anti-mitochondrial antibody M2 subtype (AMA-M2) ELISA Kit
Interleukin-6, Recombinant, Human, Western Blot Control (Interleukin-6, IL-6, B Cell Stimulatory Factor 2, BSF-2, CTL Differentiation Factor, CDF, Hybridoma Growth Factor, Interferon beta-2, IFN-beta-2, IL6, IFNB2) discontinued